Jay Backstrom, M.D., M.P.H.

Jay Backstrom, M.D., M.P.H. most recently served as executive vice president, research and development, at Acceleron Pharma through its acquisition by Merck in 2021. Previously, Dr. Backstrom was chief medical officer and head of regulatory affairs for Celgene Corporation, where he was instrumental in bringing REBLOZYL®, co-developed by Celgene and Acceleron, through to regulatory approval. Prior, he worked as vice president of clinical research and development, myelodysplastic syndrome and acute myeloid leukemia, as well as chief medical officer, through the completion of the Bristol Myers Squibb-Celgene merger in 2019. Dr. Backstrom now serves as a non-executive board director of Autolus Therapeutics, Be Biopharma and Disc Medicine. He earned his M.D. and completed medical training at the Lewis Katz School of Medicine at Temple University, and he received a Master’s in public health from the Saint Louis University School of Public Health.